Objective: To analyze the clinical differences between patients with primary intracerebral hemorrhage (ICH) with and without atrial fibrillation (AF) and assess whether the effect of the antithrombotic pretreatment on outcome is modified by the presence of AF.
Methods: In this prospective observational study, researchers from 2 university hospitals included 1,106 consecutive patients with ICH. Clinical characteristics were described and stratified by presence of AF. In-hospital and 3-month mortality and 3-month disability were analyzed, considering antithrombotic pretreatment (none, antiplatelets, or oral anticoagulants) and AF (yes/no).
Results: AF was present in 21.9% of primary ICH cases. Patients with AF-ICH were older, with more vascular risk factors, more antithrombotic pretreatment, higher clinical severity, higher hematoma volume, and higher in-hospital and 3-month mortality. Do-not-resuscitate orders were applied more frequently in AF-ICH cases. After 2 different adjustment models, mortality remained significantly higher in patients with AF-ICH. However, after introducing previous antithrombotic treatment in the model, the adjusted odds ratio for 3-month mortality was 1.45 (95% confidence interval 0.74-2.85, = 0.284) for patients with AF-ICH compared with non-AF cases. AF modified the effect of antithrombotic pretreatment on in-hospital ( = 0.077) and 3-month mortality ( = 0.008). Among patients without AF, antithrombotic pretreatment increased mortality; no effect was observed in patients with AF-ICH.
Conclusions: Patients with AF and ICH had increased mortality; however, AF had no independent effect on mortality after adjustment for antithrombotic pretreatment. Conversely, antithrombotic pretreatment had a deleterious effect on outcome in patients with ICH without AF, but no detectable effect in patients with AF with ICH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0000000000008462 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanism of exacerbation of traumatic brain injury under warfarin anticoagulation in male mice.
PLoS One
December 2024
Department of Forensic Medicine, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Introduction: Traumatic brain injury (TBI) is exacerbated in patients on antithrombotic medications, with warfarin leading to increased bleeding in some cases. However, the extent to which this bleeding increases lethality and its long-term effects remain unclear. This study aimed to investigate the exacerbation of TBI by warfarin treatment and comprehensively evaluate the impact of TBI on the anticoagulant effects of warfarin.
View Article and Find Full Text PDFSTEMI Antithrombotic Therapy: The Evolving Role of P2Y12 Inhibitor Pretreatment in Contemporary Practice.
Rev Cardiovasc Med
November 2024
Cardiology Unit, Sant'Andrea University Hospital, 00189 Rome, Italy.
Article Synopsis
- The P2Y12 receptor is crucial for platelet activation and has been a focus of research, particularly in the context of treating acute coronary syndromes (ACS) with dual therapy of aspirin and clopidogrel, as shown in the landmark CURE trial from 2001.
- Advances in interventional cardiology, including drug-eluting stents and new P2Y12 inhibitors like ticagrelor and prasugrel, have significantly changed ACS treatment but challenges still exist, particularly with ST-elevation myocardial infarction (STEMI).
- The review highlights the efficacy and safety of using P2Y12 receptor antagonists as a pretreatment strategy for STEMI, stressing the need for personalized treatment plans and the future
Background: Patients with ST-segment elevation myocardial infarction (STEMI) are often pretreated with unfractionated heparin (UFH) before a primary percutaneous coronary intervention (PPCI). UFH pretreatment is intended to lessen the thrombotic burden, but there have been conflicting study findings on its safety and efficacy. We assessed the risks and benefits of UFH pretreatment with a retrospective analysis of registry data from the STEMI network of a German metropolitan region.
View Article and Find Full Text PDFEmbolic Materials' Comparison in Meningeal Artery Embolization for Chronic Subdural Hematomas: Multicenter Propensity Score-Matched Analysis of 1070 Cases.
Neurosurgery
October 2024
Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania, USA.
Background And Objectives: Multiple preferences exist for embolic materials selection in middle meningeal artery embolization (MMAE) for chronic subdural hematoma with limited comparative literature data. Herein, we compare different embolic materials.
Methods: Consecutive patients undergoing MMAE for chronic subdural hematoma at 14 North-American centers (2018-2023) were classified into 3 groups: (a) particles, (b) Onyx, (c) n-butyl cyanoacrylate (n-BCA).
Effects of batroxobin on the antithrombotic system in patients with cerebral venous thrombosis: Clues to mechanisms.
CNS Neurosci Ther
August 2024
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- Batroxobin, when combined with anticoagulation, shows promise in improving treatment outcomes for patients with acute cerebral venous thrombosis (CVT) by reducing platelet aggregation and altering coagulation biomarkers.
- In a study with two treatment groups (one with prior anticoagulant therapy and another starting both treatments simultaneously), it was found that batroxobin significantly impacted fibrinogen and D-dimer levels, as well as thrombin time (TT) and activated partial thromboplastin time (APTT).
- Overall, the results suggest that batroxobin enhances the efficacy of anticoagulation therapy by modifying various coagulation parameters, indicating a potential role in the management of CVT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!